Latest

Five things for pharma marketers to know: Tuesday January 27

Five things for pharma marketers to know: Tuesday January 27

AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.

NPS drug approval bolsters Shire acquisition decision

NPS drug approval bolsters Shire acquisition decision

The FDA approved NPS Pharmaceuticals's rare-disease drug Friday. The company, which Shire shelled out $5.2 billion to buy, expects it to hit the market during the second-quarter.

Sanofi, Regeneron officially in PCSK9 race

Sanofi, Regeneron officially in PCSK9 race

The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.

Approval pits Novartis meningococcal vaccine against Pfizer shot

FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.

New cancer therapies raise new safety concerns

Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.

Five things for pharma marketers to know: Monday, January 26

Five things for pharma marketers to know: Monday, January 26

Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.

Headliner: Scientist CEO sets sights on Sierra Leone

Headliner: Scientist CEO sets sights on Sierra Leone

Thomas Sack, President and CEO, MRIGlobal

Five things for pharma marketers to know: Friday, January 23

Five things for pharma marketers to know: Friday, January 23

Express Scripts takes aim at high-priced cancer drugs; FDA panel recommends approval for Astellas orphan drug; GSK Ebola Vaccine could touch down in Liberia as early as next week.

Actavis CEO touts his acquisition strategy

Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.

Rx painkillers increase risk of birth defects: CDC

The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.

Agency Spotlight


This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.

Email Newsletters